Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Pharma giant Moderna (MRNA) is set to release its Q4 2024 results on February 14. MRNA stock has lost about 64% over the past ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19, is ...

In a turbulent market environment, Moderna Inc (BMV:MRNA). shares have touched a 52-week low, sinking to $30.7, with concerning financial metrics showing negative EBITDA of $2.36 billion and gross ...

and Moderna's share price sank nearly 17%. The conventional investing wisdom is that you shouldn't "try to catch a falling knife." Moderna's stock chart certainly looks like a falling knife.

Moderna (NASDAQ:MRNA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.

If you're confident in the company's ability to orchestrate a turnaround, you may view the current stock price as an attractive entry point for a long-term holding. The allure of Moderna as an ...

If we assume Moderna only hits the low end of its 2025 revenue forecast, the stock trades at roughly 9 times forward sales. That's well above the 7.2 price-to-sales ratio for the biotech industry.

If you are a believer in mRNA technology, now may be a perfect time to load up on some Moderna stock. It could benefit from AI developments and is trading at a cheap price. The stock is not risk ...